| Prev Close | 2.36 |
| Day Low/High | 2.27 / 2.43 |
| 52 Wk Low/High | 1.57 / 3.20 |
| Avg Volume | 445.70K |
Latest News
Aptose To Release Second Quarter Ended June 30, 2019 Financial Results And Hold Conference Call On August 6, 2019
SAN DIEGO and TORONTO, July 23, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc.
Aptose Doses First CLL Patient In Phase 1 Study Of CG-806 And Doses Third Cohort In Phase 1 Study Of APTO-253
- CG-806 oral non-covalent pan-FLT3/pan-BTK inhibitor being developed for the treatment of CLL and other B-cell malignancies and for AML - - APTO-253 MYC inhibitor being developed for the treatment of AML and MDS - SAN DIEGO and TORONTO, July 16,...
Aptose Reports Results For The Fourth Quarter And Year Ended December 31, 2017
Conference Call and Webcast at 5pm EDT Today
OHSU And Aptose Present CG'806 Preclinical Data At ASH 59th Annual Meeting
CG'806 reveals broad and potent single agent activity, and enhanced activity when combined with Bcl-2 or BET inhibitors, against AML and CLL patient samples
Aptose Presents New Preclinical Data On CG'806 Pan-FLT3/pan-BTK Inhibitor At ASH 59th Annual Meeting
Data elucidate unique ability of CG'806 to kill a broad range of AML cells by suppressing multiple pathways, to overcome resistance caused by bone marrow stromal cells, and to act synergistically with other agents
Aptose Reports Results For The Third Quarter Ended September 30, 2017
Conference Call and Webcast at 5pm EST Today
Aptose Enters Into $15.5 Million Common Shares Purchase Agreement With Aspire Capital Fund, LLC
Aptose Provides Corporate Update Highlights
Preclinical Data On Aptose Biosciences FLT3/BTK Inhibitor CG'806 Presented At AACR Hematologic Malignancies Meeting
Data support superiority of CG'806 relative to competitive agents against AML driven by diverse mutated forms of FLT3
OHSU And Aptose Present CG'806 Preclinical Data Demonstrating Potent Activity Against Patient Samples At AACR Hematologic Malignancies Meeting
Data support superiority of CG'806 relative to select competitive agents